US wait times for cancer surgeries are getting longer and longer
US cancer surgery wait times increased across all six major cancer types between 2012 and 2023, with delays ranging from 10 to 18 additional days depending on cancer type Healthcare system consolidation and centralization into high-volume academic centers is the primary driver, potentially offsetting the quality benefits of specialized care Wait time increases disproportionately affect socioeconomically vulnerable populations, including uninsured/Medicaid patients, Black patients, lower-income i
Analysis
TL;DR
- US cancer surgery wait times increased across all six major cancer types between 2012 and 2023, with delays ranging from 10 to 18 additional days depending on cancer type
- Healthcare system consolidation and centralization into high-volume academic centers is the primary driver, potentially offsetting the quality benefits of specialized care
- Wait time increases disproportionately affect socioeconomically vulnerable populations, including uninsured/Medicaid patients, Black patients, lower-income individuals, and those with longer travel distances
- Over 2.7 million patients with non-metastatic stage I–III cancers were studied across four time periods (2012–2015, 2016–2019, 2020–2021, 2022–2023)
- Researchers recommend that uncomplicated cases should remain at local centers rather than being referred to high-volume centers, where avoidable delays may negate clinical benefits
Why It Matters
This study reveals a critical paradox in modern healthcare: as cancer treatment quality has improved through centralization and specialization, access timeliness has deteriorated, directly impacting patient survival outcomes. For healthcare administrators and policymakers, the findings underscore that quality metrics cannot be optimized in isolation—system design must balance clinical excellence with equitable and timely access, particularly for vulnerable populations.
Technical Details
- Study scope: 2.7 million patients diagnosed with non-metastatic stage I–III cancers (breast, colon, lung, pancreatic, gastric, esophageal) requiring surgery between 2012 and 2023
- Time period analysis: Four cohorts—2012–2015, 2016–2019, 2020–2021, 2022–2023—showing incremental wait time increases across all periods
- Wait time increases: Breast cancer: 34→45 days (+11); Colon: 20→31 days (+11); Lung: 41→53 days (+12); Pancreatic: 23→32 days (+9); Gastric: 35→49 days (+14); Esophageal: 38→48 days (+10)
- Prolonged wait thresholds: Rates of waits ≥30 days and ≥60 days increased across all cancer types
- Data source: JAMA Surgery publication, led by Timothy Donahue at UCLA
Industry Insight
- Healthcare system consolidation trends should be re-evaluated through a timeliness lens; high-volume centers improve outcomes per case but create bottlenecks that may reduce net survival gains across populations
- Health systems should implement risk-stratified referral protocols, keeping uncomplicated cases at local facilities while reserving centralized centers for complex or rare cases
- Equity-focused interventions—such as transportation support, Medicaid navigation, and geographic capacity expansion—are essential to prevent vulnerable populations from bearing disproportionate delays as systems centralize
Disclaimer: The above content is generated by AI and is for reference only.